中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.011 seconds)

    ANTIGEN-BINDING MOLECULES THAT BIND CD38 AND/OR CD28, AND USES THEREOF
    4.
    发明申请
    ANTIGEN-BINDING MOLECULES THAT BIND CD38 AND/OR CD28, AND USES THEREOF 审中-公开

    公开(公告)号：WO2022061098A1

    公开(公告)日：2022-03-24

    申请号：PCT/US2021/050850

    申请日：2021-09-17

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： DILILLO, David ,  HERMANN, Aynur ,  KIRSHNER, Jessica ,  OLSON, Kara ,  SINESHCHEKOVA, Olga ,  SMITH, Eric ,  ULLMAN, Erica

    IPC: C07K16/28 ,  A61P35/00

    Abstract: CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

    CHIMERIC ANTIGEN RECEPTORS WITH MAGE-A4 SPECIFICITY AND USES THEREOF
    6.
    发明申请
    CHIMERIC ANTIGEN RECEPTORS WITH MAGE-A4 SPECIFICITY AND USES THEREOF 审中-公开

    公开(公告)号：WO2021016585A1

    公开(公告)日：2021-01-28

    申请号：PCT/US2020/043567

    申请日：2020-07-24

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： BRAY, Kevin ,  DELFINO, Frank ,  DILILLO, David ,  MEAGHER, Thomas Craig

    IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725

    Abstract: MAGE-A4, or Melanoma-Associated Antigen A4, is a cancer-testis antigen (CTA) on the X chromosome. The present disclosure provides MAGE-A4-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present disclosure are capable of inhibiting the growth of tumors expressing MAGE-A4. The engineered cells of the present disclosure are useful for the treatment of diseases and disorders in which an upregulated or induced MAGE-A4-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the MAGE-A4-specific chimeric antigen receptors of the present disclosure are useful for the treatment of various cancers.

    BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
    7.
    发明申请
    BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF 审中-公开

    公开(公告)号：WO2020018820A1

    公开(公告)日：2020-01-23

    申请号：PCT/US2019/042447

    申请日：2019-07-18

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： SMITH, Eric ,  OLSON, Kara ,  DELFINO, Frank ,  DILILLO, David ,  KIRSHNER, Jessica ,  SINESHCHEKOVA, Olga ,  ZHANG, Qian

    IPC: A61K39/00 ,  A61P35/02 ,  C07K16/28

    Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.

Patent Agency Ranking